STOCK TITAN
  1. Home
  2. News
  3. NKTX

Nkarta Announces September 2020 Virtual Investor Conference Schedule

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference:

Cantor Virtual Global Healthcare Conference
Date: Tuesday, September 15, 2020
Fireside chat presentation: 2:00 p.m. ET

A live audio webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com. A replay of the webcast will be archived on the website for approximately four weeks.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com


Stock NKTX logo
Nkarta, Inc.

NASDAQ:NKTX

NKTX Rankings

#3103 Ranked by Market Cap
#5374 Ranked by Stock Gains
N/A Ranked by Dividends

NKTX Latest News

May 9, 2024
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Apr 3, 2024
Nkarta to Participate in Upcoming Investor Conferences
Mar 25, 2024
Nkarta Announces Pricing of $240 Million Underwritten Offering
Mar 21, 2024
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Feb 28, 2024
Nkarta to Participate in Upcoming Investor Conferences

NKTX Stock Data

460.15M
33.34M
5.16%
73.51%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About NKTX

nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.